BioNTech SE (NASDAQ:BNTX) Shares Sold by Candriam S.C.A.

Candriam S.C.A. lowered its holdings in BioNTech SE (NASDAQ:BNTX - Free Report) by 8.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 846,934 shares of the company's stock after selling 80,230 shares during the quarter. Candriam S.C.A. owned 0.35% of BioNTech worth $96,508,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. First Trust Direct Indexing L.P. purchased a new position in BioNTech in the third quarter valued at about $245,000. GSA Capital Partners LLP purchased a new position in BioNTech in the 3rd quarter valued at approximately $373,000. Baillie Gifford & Co. raised its holdings in BioNTech by 0.4% during the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company's stock worth $986,750,000 after purchasing an additional 31,773 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in BioNTech during the third quarter worth $345,000. Finally, Planning Capital Management Corp grew its holdings in BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company's stock valued at $54,000 after purchasing an additional 450 shares during the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Trading Down 3.2 %

Shares of BNTX traded down $3.43 during mid-day trading on Monday, reaching $105.35. The company had a trading volume of 1,170,885 shares, compared to its average volume of 789,833. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The firm has a fifty day simple moving average of $116.91 and a 200-day simple moving average of $112.93. The stock has a market cap of $25.26 billion, a price-to-earnings ratio of -50.17 and a beta of 0.30. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

Remove Ads

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating analysts' consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.24 billion. During the same quarter last year, the firm earned $1.90 earnings per share. The firm's revenue for the quarter was down 19.5% compared to the same quarter last year. On average, sell-side analysts anticipate that BioNTech SE will post -3.88 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on BNTX. Berenberg Bank assumed coverage on shares of BioNTech in a research report on Tuesday, November 19th. They issued a "buy" rating and a $130.00 price objective on the stock. JPMorgan Chase & Co. lowered their price target on shares of BioNTech from $124.00 to $122.00 and set a "neutral" rating on the stock in a research report on Tuesday, November 26th. Canaccord Genuity Group lifted their price objective on BioNTech from $171.00 to $171.44 and gave the stock a "buy" rating in a research report on Wednesday, November 27th. HC Wainwright reiterated a "buy" rating and set a $150.00 target price on shares of BioNTech in a report on Monday, November 18th. Finally, Truist Financial assumed coverage on BioNTech in a report on Friday, January 10th. They issued a "buy" rating and a $172.00 price target for the company. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, BioNTech presently has an average rating of "Moderate Buy" and an average price target of $142.72.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.